Mecysteine

Mecysteine

SCHEMBL21033

COC(=O)[C@@H](N)CS.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Mecysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mecysteine SCHEMBL28204008 1.00 PTGS1 (0.48)
Mecysteine SCHEMBL1681697 1.00
Mecysteine SCHEMBL28204007 1.00 PTGS1 (0.48)
Mecysteine SCHEMBL1445530 1.00
Mecysteine SCHEMBL21034 0.98
Mecysteine SCHEMBL94255 0.98
Mecysteine SCHEMBL1681698 0.98
Mecysteine SCHEMBL5685917 0.95
Mecysteine SCHEMBL28732784 0.95
Mecysteine SCHEMBL5685920 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136185-A Porous layered structure nickel cobalt lithium manganate powder and preparation method thereof 桂林电子科技大学 2025-06-13 CN claimed
CN-119868307-A Hybrid nanoparticle, preparation method and application thereof 天津工业大学 2025-04-25 CN claimed
CN-119098143-B Preparation process of modified silicon dioxide adsorbent 乳山市大洋硅胶有限公司 2025-03-25 CN claimed
CN-119569599-A Synthetic method of sodium saprolite intermediate 湖南九典宏阳制药有限公司 2025-03-07 CN claimed
WO-2025047832-A1 SKIN COSMETIC COMPOSITION CONTAINING BOTRYOCOCCENE AS ACTIVE INGREDIENT フィコケミー株式会社 2025-03-06 WO claimed
CN-119098143-A Preparation process of modified silicon dioxide adsorbent 乳山市大洋硅胶有限公司 2024-12-10 CN claimed
CN-118662681-B Medical hydrocolloid dressing and preparation method thereof 江苏弘生生物工程有限公司 2024-11-08 CN claimed
CN-111892575-B Shikonin sulfur Xin Liumi twin medicine molecule and synthetic method and application thereof 南京大学 2024-10-01 CN claimed
CN-118662681-A Medical hydrocolloid dressing and preparation method thereof 江苏弘生生物工程有限公司 2024-09-20 CN claimed
CN-117886812-B Heterocyclic mercapto triazole Schiff base compound with antibacterial property and preparation method thereof 辽宁科技学院 2024-07-05 CN claimed
US-20040009263-A1 Methods for extracting corn proteins from corn gluten meal WM. WRIGLEY JR. COMPANY 2004-01-15 US claimed
JP-2003515526-A 2003-05-07 JP claimed
EP-1252133-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-10-30 EP claimed
WO-2002062154-A1 METHODS OF EXTRACTING CORN PROTEINS FROM CORN GLUTEN MEAL WM. WRIGLEY JR. COMPANY (US) 2002-08-15 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
WO-2001012584-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2001-02-22 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5700410-A Method of manufacturing wax matrices NIPPON SHINYAKU CO., LTD. (JP) 1997-12-23 US claimed
EP-0580860-B1 METHOD OF MANUFACTURING SOLID DISPERSION NIPPON SHINYAKU CO LTD (JP) 1997-10-22 EP claimed